Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06756932
Registration number
NCT06756932
Ethics application status
Date submitted
24/12/2024
Date registered
3/01/2025
Date last updated
14/09/2026
Titles & IDs
Public title
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Query!
Scientific title
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer
Query!
Additional trial identifiers [1]
0
0
CTR20250114
Query!
Additional trial identifiers [2]
0
0
BGB-21447-102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Hormone-receptor-positive Breast Cancer
0
0
Query!
HER2-negative Breast Cancer
0
0
Query!
Metastatic Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - BGB-21447
Treatment: Drugs - Fulvestrant
Treatment: Drugs - BGB-43395
Experimental: Part 1A: BGB-21447 + Fulvestrant - Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant.
Experimental: Part 1B: BGB-21447 + BGB-43395 + Fulvestrant - Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant and BGB-43395.
Experimental: BGB-21447 + Fulvestrant Food Effect Substudy - Participants will receive BGB-21447 at the recommended dose with a high-fat meal and under a fasted state in combination with fulvestrant.
Experimental: Part 2: Dose Expansion, BGB-21447 + Fulvestrant - Participants will receive BGB-21447 at the recommended dose(s) for expansion determined in Part 1A in combination with fulvestrant.
Treatment: Drugs: BGB-21447
Administered orally.
Treatment: Drugs: Fulvestrant
Administered via intramuscular injection.
Treatment: Drugs: BGB-43395
Administered orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and AEs that meet protocol-defined dose-limiting toxicity criteria.
Query!
Timepoint [1]
0
0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
Query!
Primary outcome [2]
0
0
Part 1: Recommended Dose for Expansion (RDFE) of BGB-21447 in combination with fulvestrant and in combination with fulvestrant and BGB-43395
Query!
Assessment method [2]
0
0
RDFE of BGB-21447 in combination with fulvestrant and in combination with fulvestrant and BGB-43395 will be determined based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Query!
Timepoint [2]
0
0
From first dose of the study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 6 to 9 months
Query!
Primary outcome [3]
0
0
Part 2: Objective Response Rate (ORR)
Query!
Assessment method [3]
0
0
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Query!
Timepoint [3]
0
0
Approximately 12 months
Query!
Secondary outcome [1]
0
0
Part 1: ORR
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants who had confirmed CR or PR as assessed by the investigator per RECIST v1.1.
Query!
Timepoint [1]
0
0
Approximately 12 months
Query!
Secondary outcome [2]
0
0
Parts 1 and 2: Duration of Response (DOR)
Query!
Assessment method [2]
0
0
DOR is defined as the time from the first determination of an objective response until the first documentation of progression or death, whichever comes first, as assessed by the investigator per RECIST v1.1.
Query!
Timepoint [2]
0
0
Approximately 12 months
Query!
Secondary outcome [3]
0
0
Part 1:Time to Response (TTR)
Query!
Assessment method [3]
0
0
TTR is defined as the time from the date of the first dose of study drug to the date of the first CR or PR, as assessed by the investigator per RECIST v1.1.
Query!
Timepoint [3]
0
0
Approximately 12 months
Query!
Secondary outcome [4]
0
0
Part 2: Disease Control Rate (DCR)
Query!
Assessment method [4]
0
0
DCR is defined as the percentage of participants with best overall response of a CR, PR, and stable disease.
Query!
Timepoint [4]
0
0
Approximately 12 months
Query!
Secondary outcome [5]
0
0
Part 2: Clinical Benefit Rate (CBR)
Query!
Assessment method [5]
0
0
CBR is defined as the percentage of participants who achieve CR, PR, or durable stable disease (stable disease = 24 weeks).
Query!
Timepoint [5]
0
0
Approximately 12 months
Query!
Secondary outcome [6]
0
0
Part 2: Progression-Free Survival (PFS)
Query!
Assessment method [6]
0
0
PFS is defined as the time from the date of the first dose of study drug to the date of the first documentation of progressive disease as assessed by the investigator, or death, whichever occurs first. The progressive disease assessment is based on RECIST v1.1.
Query!
Timepoint [6]
0
0
Approximately 12 months
Query!
Secondary outcome [7]
0
0
Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [7]
0
0
Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.
Query!
Timepoint [7]
0
0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
Query!
Secondary outcome [8]
0
0
Maximum observed plasma concentration (Cmax) of BGB-21447 and BGB-43395
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to approximately 2 months
Query!
Secondary outcome [9]
0
0
Time to reach maximum observed plasma concentration (Tmax) of BGB-21447 and BGB-43395
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Up to approximately 2 months
Query!
Secondary outcome [10]
0
0
Area under the concentration-time curve (AUC) of BGB-21447 and BGB-43395
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Up to approximately 2 months
Query!
Secondary outcome [11]
0
0
Apparent terminal elimination half-life (t1/2) of BGB-21447 and BGB-43395
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to approximately 2 months
Query!
Secondary outcome [12]
0
0
Food Effect Substudy: AUC of BGB-21447 under fasted and fed state
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to approximately 2 months
Query!
Secondary outcome [13]
0
0
Food Effect Substudy: Cmax of BGB-21447 under fasted and fed state
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Up to approximately 2 months
Query!
Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed HR+/HER2- metastatic breast cancer. Part 1A and 1B: Participants must have received = 1 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting. Part 2: Participants must have received 1-3 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting.
* Female participants will be required (either continue ongoing or initiate as soon as feasible) to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.
* Male participants may be required to use GnRH agonists when being treated with fulvestrant at the discretion of the investigator.
* Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of = 1.
* Adequate organ function.
* Female participants of childbearing potential and nonsterile male participants with female partners of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for 7 days after the last dose of BGB-21447, 6 months after the last dose of BGB-43395, and 2 years after the last dose of fulvestrant.
* Food effect substudy only: Participants who are able and willing to fast overnight (= 10 hours) and consume a high-fat meal.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Prior Bcl-2 inhibitor exposure. For triplet combination cohorts only: Prior therapy selectively targeting CDK4.
* Known leptomeningeal disease or uncontrolled, untreated brain metastases.
* Any malignancy = 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, treated papillary thyroid carcinoma, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
* For Part 1B: Uncontrolled diabetes.
* History of hepatitis B or active Hepatitis C infection
* China Only: Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA > 500 IU/ml (or > 2500 copies/ml) at screening.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/02/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/07/2027
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Saint Vincents Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [3]
0
0
Sunshine Coast University Private Hospital - Birtinya
Query!
Recruitment hospital [4]
0
0
Peter Maccallum Cancer Centre - Melbourne
Query!
Recruitment hospital [5]
0
0
Western Health Sunshine Hospital - St Albans
Query!
Recruitment hospital [6]
0
0
Linear Clinical Research - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
NSW 2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
NSW 2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
QLD 4575 - Birtinya
Query!
Recruitment postcode(s) [4]
0
0
VIC 3000 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
VIC 3021 - St Albans
Query!
Recruitment postcode(s) [6]
0
0
WA 6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Iowa
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Washington
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Guangdong
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Henan
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Shanghai Municipality
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Tianjin Municipality
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Zhejiang
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
BeOne Medicines
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06756932
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
BeOne Medicines
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Director
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1.877.828.5568
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
See plan description
Query!
Available to whom?
See plan description
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://beonemedicines.com/science/clinical-trials/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06756932
Download to PDF